News & Events


Tuesday December 07, 2021

Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease

- Highly Statistically Significant Reduction in Chorea Movements (p

Tuesday November 30, 2021

Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer

SAN DIEGO , Nov. 30, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that Jude Onyia , Ph.D., has joined the company's executive management team as Chief Scientific Officer. Dr. Onyia , a scientist with more than 25 years of experience in the pharmaceutical

Monday November 22, 2021

Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders

Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878 in schizophrenia in 2022 and Phase 1 studies for a dual M1/M4 and selective M1 agonist in 2023 Sosei Heptares receives US$100 million upfront, ongoing R&D funding, and up to US$2.6 billion in

Tuesday November 09, 2021

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

SAN DIEGO , Nov. 9, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:     Kevin Gorman , Chief Executive Officer, and Matt Abernethy , Chief Financial Officer will present at

Monday November 01, 2021

Neurocrine Biosciences Reports Third Quarter 2021 Financial Results

INGREZZA® (valbenazine) Third Quarter 2021 Net Product Sales of $287 Million with Approximately 52,000 Total Prescriptions SAN DIEGO , Nov. 1, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2021 .